Kaiyuan ZHU, CTO of 6J Biotechnology.
Dr. ZHU is graduated from the Joint Ph.D program from Cornell University and City University of Hong Kong. He received Master of Philosophy (M.Phil.) degree from the Schoole of Medicine, University of Hong Kong, and Bachelor degree from Wuhan University, China. He conducted research on the signaling pathway on centrosome orientation in mitosis and developed the potential therapeutic drug for acute myeloid leukemia therapy.
